U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07813572) titled 'ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular' on Sept. 04.
Brief Summary: The purpose of the study is to evaluate the efficacy of ZG005 combined with bevacizumab compared with sintilimab combined with bevacizumab in the first-line treatment of participants with advanced HCC
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Carcinoma
Intervention:
DRUG: ZG005 for Injection
Participants receive ZG005 20 mg/kg IV, Q3W
DRUG: Bevacizumab ( Avastin)
Participants receive Bevacizumab ( Avastin) 15 mg/kg IV, Q3W
DRUG: Sintilimab
Participan...